Viking Therapeutics Inc(VKTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:42 PM ET (Korea 10/28 05:42)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.66 | Insider Own | 2.93% | Shs Outstand | 127.2M | Perf Week | -6.81% |
| Market Cap | 3.17B | Forward P/E | - | EPS next Y | 5.49% | Insider Trans | -4.8% | Shs Float | 123.4M | Perf Month | -24.64% |
| Enterprise Value | 2.67B | PEG | - | EPS next Q | -1.06 | Inst Own | 59.4% | Short Float | 20.69% | Perf Quarter | -25.55% |
| Income | -0.53B | P/S | - | EPS this Y | -44.14% | Inst Trans | 1.95% | Short Ratio | 5.54 | Perf Half Y | -23.16% |
| Sales | 0.00B | P/B | 7.11 | EPS next 5Y | -1.83% | ROA | -79.24% | Short Interest | 25.54M | Perf YTD | -29.25% |
| Book/sh | 3.5 | P/C | 6.31 | EPS past 3/5Y | -52.71% -42.46% | ROE | -88.85% | 52W High | -42.32% ($43.15) | Perf Year | -30.73% |
| Cash/sh | 3.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -129.73% | 52W Low | 3.69% ($24.00) | Perf 3Y | 169.37% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -203.77% | Gross Margin | - | Volatility(W/M) | 5.04% 5.5% | Perf 5Y | 326.2% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.71 | Perf 10Y | 2183.49% |
| Dividend Ex-Date | - | Quick Ratio | 4.72 | EPS Q/Q | -88.32% | Profit Margin | - | RSI (14) | 38.48 | Recom | 1.19 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.72 | Sales Q/Q | - | SMA20 | -8.82% ($27.3) | Beta | 0.76 | Target Price | $95.05 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/28 | SMA50 | -19.7% ($31) | Rel Volume | 0.71 | Prev Close | $24.21 |
| Employees | 53 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 10.77% - | SMA200 | -23.39% ($32.49) | Avg Volume(3M) | 4.61M | Price | $24.89 |
| IPO | 2015/4/29 | Option/Short | Yes/Yes | Trades | 22756 | Volume | 3,290,323 | Change | 2.81% |
A clinical-stage biotech company developing treatments for metabolic and obesity-related diseases. It is developing therapeutics targeting obesity, metabolic disorders, and liver diseases, drawing investor attention as its lead obesity treatment candidate advances through clinical trials. A biotech firm specialized in obesity and metabolic therapies.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded less than usual. That is 71% of its average volume.
Next earnings report: October 28
1 days to go.
VKTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -44.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +326.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #70 of 594 in the industry
Based on market cap of $3B.
IDYA#68 Ideaya Biosciences Inc $3B PER - 
ELVN#69 Enliven Therapeutics Inc $3B PER - VKTX#70 Viking Therapeutics Inc $3B PER - 
DYN#71 Dyne Therapeutics Inc $3B PER - 
TLX#72 Telix Pharmaceuticals Ltd ADR $3B PER 96.6 
FAQ
What kind of company is VKTX?
VKTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VKTX?
The market cap of VKTX is approximately $3.2B, ranking 1,715 within its sector.
What is the 52-week high and low for VKTX?
VKTX has recorded a 52-week high of $43.15 and a low of $24.00.
